NCT00673920View on ClinicalTrials.gov

A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

PHASE3TerminatedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

April 24, 2008

Primary Completion Date

October 26, 2009

Study Completion Date

October 26, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Methotrexate

Oral or parenteral repeating dose

DRUG

Ocrelizumab

"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."

DRUG

Placebo

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Genentech, Inc.

INDUSTRY

NCT00673920 - A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy | Biotech Hunter | Biotech Hunter